Multiplexed molecular diagnostics are generating great momentum across an increasingly wide spectrum of investigations. Their promise of cost and labor efficiencies and consumer-level ease of use is compelling.
Our latest report, 10 Inevitable Drivers of Molecular Diagnostics, outlines why we believe this approach will soon dominate point-of-care, central lab, and at-home testing for the foreseeable future.
This quick-read article can help your team think about multiplexed MDx strategies across several critical dimensions, including:
ECONOMIC PRIORITIES
Conserving labor and improving lab efficiencies
COMPETITIVE PRIORITIES
Keeping up with market demand and best practices
EFFICIENCY PRIORITIES
Helping labs address higher volumes & staffing shortages
CONSUMER PRIORITIES
Device miniaturization and broader, sophisticated panels
PUBLIC HEALTH PRIORITIES
Stewardship for diverse populations and rapid scale-up
10 Inevitable Drivers of Molecular Diagnostics
Take a few minutes to digest this evidence-driven forecast and share it with your MDx development team to help brainstorm your most effective response.